Hospital Pharmacy Europe

1 week ago | hospitalpharmacyeurope.com | Helena Beer

Patients’ gender, age and ethnicity significantly influence the likelihood of having a medication-related error formally reported, according to a cross-sectional study by Barts Health NHS Trust in London, UK. The findings of this first report assessing possible disparities in medicine-related incident reporting in England highlight that systematic support is required to reduce the variation of medicine error reporting among patients with key protected characteristics.

2 weeks ago | hospitalpharmacyeurope.com | Helena Beer

A simple, multifaceted antibiotic stewardship programme significantly improves adherence to guidelines for treating non-severe community-acquired pneumonia in children, a quasi-experimental before and after study conducted at Nantes University Hospital has demonstrated. Electronic health record screening using predefined keywords identified 519 children between birth and 15 years and three months of age for inclusion in the study.

2 weeks ago | hospitalpharmacyeurope.com | Helena Beer

The ways in which children and adolescents with severe asthma and/or moderate-to-severe atopic dermatitis perceive their medication and quality of life has been assessed in a real-world exploratory study, with particular focus on dupilumab. The study included 57 paediatric patients (severe asthma: n = 31; moderate-to-severe atopic dermatitis: n = 21; both: n = 5) with a median age of 11 years and each received one structured interview with a trained pharmacist.

2 weeks ago | hospitalpharmacyeurope.com | Helena Beer

The Congress of the European Society of Clinical Microbiology and Infectious Diseases – known as ESCMID Global – brings together leading experts in infectious diseases and clinical microbiology to exchange ideas and explore the latest innovations and cutting-edge research. Here, Gerry Hughes reports on some of the key themes and highlights from the recent 2025 gathering. The escalating global threat of antimicrobial resistance (AMR) demands evidence-informed, multidisciplinary action.

3 weeks ago | hospitalpharmacyeurope.com | Helena Beer

Nirmatrelvir plus ritonavir is no longer recommended for some risk groups including the over-70s, the National Institute for Health and Care Excellence (NICE) has said in updated guidance. The antiviral, also known by its brand name Paxlovid, is no longer cost effective in the over-70s as well as people with diabetes, obesity and heart failure, the new recommendations said.